[go: up one dir, main page]

WO2025011440A3 - Ophthalmic preparation containing recombinant human β-nerve growth factor and use thereof - Google Patents

Ophthalmic preparation containing recombinant human β-nerve growth factor and use thereof Download PDF

Info

Publication number
WO2025011440A3
WO2025011440A3 PCT/CN2024/103736 CN2024103736W WO2025011440A3 WO 2025011440 A3 WO2025011440 A3 WO 2025011440A3 CN 2024103736 W CN2024103736 W CN 2024103736W WO 2025011440 A3 WO2025011440 A3 WO 2025011440A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
recombinant human
nerve growth
ophthalmic preparation
preparation containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2024/103736
Other languages
French (fr)
Chinese (zh)
Other versions
WO2025011440A2 (en
Inventor
李树刚
于廷和
蒋竺芸
刘涛
袁雪
辛渝
杨丹丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kerun Biopharm
Original Assignee
Kerun Biopharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kerun Biopharm filed Critical Kerun Biopharm
Publication of WO2025011440A2 publication Critical patent/WO2025011440A2/en
Publication of WO2025011440A3 publication Critical patent/WO2025011440A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

An ophthalmic preparation containing a recombinant human β-nerve growth factor. The ophthalmic preparation contains the following components in parts by weight: 0.005-1 parts of a recombinant human nerve growth factor, 20-70 parts of trehalose, 5-30 parts of mannitol, and 1-13 parts of polyvinyl alcohol.
PCT/CN2024/103736 2023-07-07 2024-07-05 Ophthalmic preparation containing recombinant human β-nerve growth factor and use thereof Pending WO2025011440A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310835893.0 2023-07-07
CN202310835893.0A CN119258198A (en) 2023-07-07 2023-07-07 Composition containing recombinant human nerve growth factor and its application and ophthalmic preparation

Publications (2)

Publication Number Publication Date
WO2025011440A2 WO2025011440A2 (en) 2025-01-16
WO2025011440A3 true WO2025011440A3 (en) 2025-02-27

Family

ID=94113961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2024/103736 Pending WO2025011440A2 (en) 2023-07-07 2024-07-05 Ophthalmic preparation containing recombinant human β-nerve growth factor and use thereof

Country Status (2)

Country Link
CN (1) CN119258198A (en)
WO (1) WO2025011440A2 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101972224A (en) * 2010-09-13 2011-02-16 舒泰神（北京）生物制药股份有限公司 Eye in-situ gel
CN101972470A (en) * 2010-09-13 2011-02-16 舒泰神（北京）生物制药股份有限公司 In-situ gel composition for eyes
WO2016169455A1 (en) * 2015-04-21 2016-10-27 舒泰神（北京）生物制药股份有限公司 Nerve growth factor composition and powder injection
WO2016169453A1 (en) * 2015-04-21 2016-10-27 舒泰神（北京）生物制药股份有限公司 Nerve growth factor composition and powder injection
WO2016169454A1 (en) * 2015-04-21 2016-10-27 舒泰神（北京）生物制药股份有限公司 Nerve growth factor composition and powder injection
CN107913246A (en) * 2016-10-09 2018-04-17 刘力 The medical composite for eye of local administration
CN112826829A (en) * 2019-11-25 2021-05-25 多姆皮制药公司 Ophthalmic preparations
CN116036240A (en) * 2023-02-01 2023-05-02 白帆生物科技(上海)有限公司 A liquid preparation of stable recombinant human nerve growth factor

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101972224A (en) * 2010-09-13 2011-02-16 舒泰神（北京）生物制药股份有限公司 Eye in-situ gel
CN101972470A (en) * 2010-09-13 2011-02-16 舒泰神（北京）生物制药股份有限公司 In-situ gel composition for eyes
WO2016169455A1 (en) * 2015-04-21 2016-10-27 舒泰神（北京）生物制药股份有限公司 Nerve growth factor composition and powder injection
WO2016169453A1 (en) * 2015-04-21 2016-10-27 舒泰神（北京）生物制药股份有限公司 Nerve growth factor composition and powder injection
WO2016169454A1 (en) * 2015-04-21 2016-10-27 舒泰神（北京）生物制药股份有限公司 Nerve growth factor composition and powder injection
CN107913246A (en) * 2016-10-09 2018-04-17 刘力 The medical composite for eye of local administration
CN112826829A (en) * 2019-11-25 2021-05-25 多姆皮制药公司 Ophthalmic preparations
CN116036240A (en) * 2023-02-01 2023-05-02 白帆生物科技(上海)有限公司 A liquid preparation of stable recombinant human nerve growth factor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DONIA, M. ET AL.: "Polypeptide and Glycosaminoglycan Polysaccharide as Stabilizing Polymers in Nanocrystals for a Safe Ocular Hypotensive Effect", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 162, 8 August 2020 (2020-08-08), pages 1699 - 1710, XP086280694, DOI: 10.1016/j.ijbiomac.2020.07.306 *
WU, YU ET AL.: "Long-acting Nanoparticle-loaded Bilayer Microneedles for Protein Delivery to the Posterior Segment of the Eye", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 165, 26 May 2021 (2021-05-26), pages 306 - 318, XP086615550, DOI: 10.1016/j.ejpb.2021.05.022 *

Also Published As

Publication number Publication date
WO2025011440A2 (en) 2025-01-16
CN119258198A (en) 2025-01-07

Similar Documents

Publication Publication Date Title
Okita et al. In vivo and in vitro studies on soft denture materials: microbial adhesion and tests for antibacterial activity
CA2495621A1 (en) Methods and apparatus for delivery of ocular implants
CA2347707A1 (en) Foldable ophthalmic and otorhinolaryngological device materials
EP2275120A3 (en) Protein-based streptococcus pneumoniae vaccines
IE880533L (en) Pharmaceutical delivery device
GB0211118D0 (en) Vaccines
EA200101156A1 (en) DRUG COMPOSITIONS OF A NEW TYPE ON THE BASIS OF POSSESSING HOLYNTHERGIC ACTION OF COMPOUNDS AND β-MIMETIC
AU2243092A (en) Extended-release form of diltiazem
EP1466606A3 (en) Use of inosine for the manufacture of a medicament for stimulating axonal outgrowth of central nervous system neurons
EP1535929A3 (en) Megakaryocyte stimulating factors
CA2112014A1 (en) Antiallergic composition for ophthalmic or nasal use
WO2001039803A3 (en) Interleukin-1 muteins useful as vaccine adjuvants
AU7266991A (en) 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions
NZ503538A (en) Moxifloxacin formulation characterised by the release times containing hydroxypropylmethylcellulose or polyvinylpyrrolidone as binder and ethylcellulose as film forming polymer
WO2025011440A3 (en) Ophthalmic preparation containing recombinant human β-nerve growth factor and use thereof
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
CA2063273A1 (en) Surfactant compositions and methods
CN208859380U (en) A protective LED lawn light
EP0373771A3 (en) New pharmaceutical uses for cystatins
EP0378413A3 (en) Compositions for topical treatment of skin disorders
CA2434911A1 (en) Use of l-carnitine as stabilizing agent of proteins
ITRM920408A0 (en) CULTURES OF DIFFERENTIATED CONJUNCTIVAL MUCOSA TISSUE, PROCEDURE FOR THEIR PREPARATION AND SUPPORTS FOR THEIR USE.
NO950950L (en) Pharmaceutical preparation
CA2003981A1 (en) Pharmaceutical compositions and use thereof in the treatment of psoriasis
IE831551L (en) Eye ointment.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24838693

Country of ref document: EP

Kind code of ref document: A2